Fig. 2
Gal-9-ERC suppressed T cell proliferation in vitro. Splenocytes (5 × 105) were harvested from C57BL/6 mice and activated by the stimulants (IL-2 + anti-CD3/CD28 Abs). Then, ERC, Gal-9-ERC (IFN-γ pre-stimulate, 20 ng/ml, 72 h), and ERC + lactose were co-cultivated with the above activated splenocytes respectively. After 96 h of co-cultivation, the splenocytes were collected for FACS analysis. a Representative dot plots of CD4+T (CD3+CD4+) and CD8+T (CD3+CD8+) cells. b, c Percentage of CD8+T (CD3+CD8+) and CD4+T (CD3+CD4+) cells (n = 6). d Representative dot plots of Th1 (CD4+IFN-γ+) and Th17 (CD4+IL-17+) cells. e, f Percentage of Th1 (CD4+IFN-γ+) and Th17 (CD4+IL-17+) cells (n = 6). Differences among groups were assessed by using one-way analysis of variance (ANOVA).*p < 0.05, **p < 0.01. Abbreviations: ERC, endometrial regenerative cell; Gal-9-ERC, Galectin-9 high-expression ERC